On December 10th, 2021, BIOQuébec and other players in the life sciences industry in Quebec sent several federal elected officials their serious concerns regarding the coming into force of the PMPRB reform. As leading representatives of the Quebec life sciences sector who actively and strategically contribute to the country's economy, they asked that the implementation of the PMPRB reform be suspended. A year later, on December 5th, 2022, new developments compel Montréal InVivo, Sherbrooke Innopole and BIOQuébec to reiterate this request. A new request for the postponement of the coming into force of new guidelines has therefore been formulated as part of the PMPRB's consultation process.
Read MoreOur executive director, Emmanuelle Toussaint, at BIOQuébec had the honor of participating to the “Rendez-Vous Politique de la Fédération des chambres de commerce du Québec (FCCQ)” with Canada’s Minister of Health, Jean-Yves Duclos
Read MoreInnovative Medicines Canada’s (IMC) initial interpretation of the Patented Medicine Prices Review Board’s (PMPRB) revised draft Guidelines is that they will further reduce the availability of new medicines in Canada by exacerbating an already unpredictable regulatory environment.
Read MoreThe Patented Medicine Prices Review Board (PMPRB) published its first edition of a publication providing information on new drugs launched in Canada and other international markets.
Read More